Published Time: 2017-05-08T01:00:00-04:00
Araim Pharmaceuticals announced that its drug candidate, Cibinetide (ARA 290), has demonstrated the ability to regenerate small nerve fibers and improve neuropathic clinical symptoms in patients with sarcoidosis, an orphan disease.
The findings are based on clinical research investigating the effects of Cibinetide on sarcoidosis-associated small fiber neuropathy. The study showed significant regeneration of small nerve fibers, which are crucial for pain and temperature sensation, leading to measurable improvements in patient symptoms.
Sarcoidosis is a complex inflammatory disease that can affect multiple organs, including the nervous system. Neuropathic pain and small fiber neuropathy are debilitating complications for which treatment options are limited. The regeneration of nerve fibers represents a potential breakthrough in addressing this unmet medical need.
Cibinetide is a synthetic peptide designed to activate the innate repair receptor, a pathway involved in tissue protection and repair. Its mechanism focuses on reducing inflammation and promoting healing, which is particularly relevant for chronic conditions like sarcoidosis.
The improvement in neuropathic symptoms suggests Cibinetide could offer a new therapeutic approach for managing the neurological manifestations of sarcoidosis, potentially improving quality of life for patients.
This news release contains forward-looking statements regarding the potential of Cibinetide. Further clinical studies are necessary to confirm these findings and support regulatory approvals.
